Cue Biopharma (CUE) Insider Ray Sumita Sells $52K of Stock
Chief Legal Compliance Officer Ray Sumita sold shares valued at over $51,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ray Sumita, Chief Legal Compliance Officer at Cue Biopharma, Inc. ($CUE), sold 1,844 shares at an average price of $28.05, worth about $51,724.20, on October 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CUE is down 32.1% to date (from the $24.61 close on Oct 12, 2026).
CUE
Cue Biopharma, Inc.
Key Points
- On October 12, 2026, Ray Sumita sold 1,844 shares of Cue Biopharma at $28.05 each for a total of $51,724.2.
- The stock recently traded around $17.98, significantly below its 52-week high of $45.50.
- Analysts have a mean price target of $88.00 for Cue Biopharma, reflecting a potential upside from current levels.
Get $CUE trade alerts by text
We text you when insiders, Congress or big funds trade $CUE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cue Biopharma, Inc. alert may contain errors. Disclosures
Ray Sumita, Chief Legal Compliance Officer at Cue Biopharma, Inc. (NasdaqCM: CUE), sold 1,844 shares on October 12, 2026. The shares were sold at $28.05 each, totaling $51,724.2.
Inside Ray Sumita's Trade
Sumita's sale was not pre-planned, and it occurred on the same day as other insiders' trades. His transaction adds to a series of insider sales on October 12, which included CEO Lin Shao-Lee and VP Michael Vincent.
Other Institutional Activity in Cue Biopharma
Several institutional investors have recently increased their stakes in Cue Biopharma. Bleichroeder LP grew its holdings by 143,381 shares, holding a total of 370,682 shares valued at about $6.19 million. Driehaus Capital Management, LLC added 146,072 shares for a total of 292,144 shares worth approximately $4.88 million. Vanguard Capital Management LLC increased its position by 79,785 shares, ending with 161,700 shares valued at around $2.70 million. Ikarian Capital, LLC and Tetragon Partners GP Ltd. also made significant additions to their positions.
Cue Biopharma, Inc. Stock Down 3.7%
Cue Biopharma's stock is currently trading below its moving averages, with a recent price of $17.98 as of October 16, 2026. This price is about 60.5% lower than its 52-week high of $45.50 and 34.8% below its 50-day moving average of $27.56.
Recent Earnings
Cue Biopharma reported trailing twelve-month revenue of $37.66 million, with a revenue growth of 166.7% year-over-year. However, the company has not been profitable, showing a negative earnings per share (EPS) of -$29.59.
Insider Buying and Selling at Cue Biopharma, Inc.
On the same day as Sumita's sale, CEO Lin Shao-Lee sold 11,087 shares for about $305,490. Additionally, VP Michael Vincent sold 1,144 shares at the same price of $28.05, totaling $32,089. Both trades were not pre-planned.
Analysts Set New Price Targets
On September 18, 2026, B. Riley Securities initiated coverage of Cue Biopharma with a "Buy" rating and a price target of $83.00. The current consensus price target among analysts is $88.00, suggesting a strong outlook for the stock despite recent insider selling.
About Cue Biopharma
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Boston, MA. It focuses on developing therapies for immunological disorders, with its lead product, CUE-221, currently in Phase 2 trials for allergic diseases. The company also utilizes its Immuno-STAT platform to target disease-specific T cells.
Related Filing Alerts
Source: Ray Sumita's Form 4 filing on $CUE (Oct 12, 2026). Find the original filing: CUE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts